Print Page

給 醫 護 專 業 人 員 的 信
 
PRAC concludes review of signal of increased risk of major cardiovascular events and cancer with Xeljanz (Letter to Healthcare Professionals) (English only)
 
 
 
附件:
  1. PRAC concludes review of signal of increased risk of major cardiovascular events and cancer with Xeljanz (English only)  
Related Information:
Singapore: Janus Kinase (JAK) inhibitors and risk of major adverse cardiovascula... 上載於 2022-12-14
Singapore: Risk of major adverse cardiovascular events, malignancy, thrombosis a... 上載於 2022-11-18
European Union: EMA confirms measures to minimise risk of serious side effects w... 上載於 2022-11-12
Canada: Canadian labelling for all JAK inhibitors to include risks of serious he... 上載於 2022-11-02
EMA recommends measures to minimise risk of serious side effects with Janus kina... 上載於 2022-10-31
European Union: EMA recommends measures to minimize risk of serious side effects... 上載於 2022-10-29
Canada: Summary Safety Review - Xeljanz/Xeljanz XR (tofacitinib), Olumiant (bari... 上載於 2022-09-17
European Union: EMA starts safety review of Janus kinase inhibitors for inflamma... 上載於 2022-02-12
Canada: Safety review found a link between the use of Xeljanz／Xeljanz XR (tofaci... 上載於 2022-01-13
The United Kingdom: Tofacitinib (Xeljanz▼): new measures to minimise risk of maj... 上載於 2021-10-07
The United States: FDA requires warnings about increased risk of serious heart-r... 上載於 2021-09-02
European Union: PRAC concludes review of signal of increased risk of major cardi... 上載於 2021-06-12
Canada: Health Canada has initiated a safety review on Xeljanz and Xeljanz XR (t... 上載於 2021-04-07
Singapore: Risk of major adverse cardiovascular events and malignancies (excludi... 上載於 2021-03-31
The United States: Initial safety trial results find increased risk of serious h... 上載於 2021-02-05
 
back